0001209191-17-056207.txt : 20171005
0001209191-17-056207.hdr.sgml : 20171005
20171005193508
ACCESSION NUMBER: 0001209191-17-056207
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171003
FILED AS OF DATE: 20171005
DATE AS OF CHANGE: 20171005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thorp Clay
CENTRAL INDEX KEY: 0001592380
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37783
FILM NUMBER: 171125548
MAIL ADDRESS:
STREET 1: C/O HATTERAS VENTURE PARTNERS III, LP
STREET 2: 280 S. MANGUM ST., SUITE 350
CITY: DURHAM
STATE: NC
ZIP: 27701
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clearside Biomedical, Inc.
CENTRAL INDEX KEY: 0001539029
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452437375
STATE OF INCORPORATION: GA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30005
BUSINESS PHONE: 678-270-3631
MAIL ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30005
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-03
0
0001539029
Clearside Biomedical, Inc.
CLSD
0001592380
Thorp Clay
C/O CLEARSIDE BIOMEDICAL, INC.
900 NORTH POINT PARKWAY, SUITE 200
ALPHARETTA
GA
30005
1
0
1
0
Common Stock
2017-10-03
4
S
0
15000
8.64
D
3856394
I
See Footnotes
Common Stock
2017-10-04
4
S
0
14000
8.59
D
3842394
I
See Footnotes
Common Stock
2017-10-05
4
S
0
6000
8.34
D
3836394
I
See Footnotes
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017.
Consists of (i) 441 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 5,752 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 522 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 930 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 7,355 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").
This transaction was executed in multiple trades at prices ranging from $8.37 to $9.09, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
Consists of (i) 412 shares sold by Hatteras NC, (ii) 5,369 shares sold by HVP III, (iii) 487 shares sold by HVA III, (iv) 868 shares sold by HVP IV and (v) 6,864 shares sold by HVP IV SBIC.
This transaction was executed in multiple trades at prices ranging from $8.33 to $8.975, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Consists of (i) 176 shares sold by Hatteras NC, (ii) 2,301 shares sold by HVP III, (iii) 209 shares sold by HVA III, (iv) 372 shares sold by HVP IV and (v) 2,942 shares sold by HVP IV SBIC.
This transaction was executed in multiple trades at prices ranging from $8.05 to $8.46, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
/s/ Brian F. Leaf, Attorney-in-Fact for Clay Thorp
2017-10-05